Recurrent Childhood Ependymoma Clinical Trial
Official title:
Phase I Study of Cilengitide (EMD 121974) in Children With Refractory Brain Tumors
This phase I trial is studying the side effects and best dose of cilengitide in treating children with recurrent, progressive, or refractory primary CNS tumors. Cilengitide may slow the growth of brain cancer cells by stopping blood flow to the tumor.
PRIMARY OBJECTIVES:
I. To describe the acute and dose-limiting toxicities (DLT) and define the maximum tolerated
dose (MTD) of cilengitide (EMD 121974) when administered to children and adolescents with
refractory primary brain tumors.
SECONDARY OBJECTIVES:
I. To obtain preliminary evidence of biologic activity by determining alterations in tissue
perfusion, tumor blood flow and metabolic activity using MR perfusion, PET and MRS and
correlating these findings with changes in tumor size by volumetric MRI.
II. To characterize inter- and intra-patient variability in the pharmacokinetics of
cilengitide and to estimate cilengitide renal clearance in this patient population.
III. To characterize the pharmacogenetic polymorphisms in drug transporters (e.g., MRP4,
BCRP) and relate to cilengitide disposition.
IV. To evaluate changes in circulating endothelial cells (CECs) and circulating endothelial
precursors (CEPs) in patients treated with cilengitide, and to investigate the correlation
between changes in CECs and CEPs, plasma, serum and urine angiogenic protein levels such as
VEGF, and clinical outcome.
V. To obtain preliminary information about the efficacy of cilengitide in this patient
population.
OUTLINE: This is a dose-escalation, multicenter study.
Patients receive cilengitide (EMD 121974) IV over 1 hour twice weekly. Treatment repeats
every 4 weeks for 13 courses in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of cilengitide until the maximum tolerated
dose (MTD) is determined. The MTD is defined as the dose at which 25% of patients are
expected to experience dose-limiting toxicity. Once the MTD is determined, 6 additional
patients are accrued and treated at that dose level for a total of 12 patients at the MTD.
Patients receiving treatment are followed weekly for the first three months then monthly for
one year or 13 courses of treatment. Patients discontinuing treatment will be followed for
resolution of all adverse events occurring while on treatment and/or within 30 days of the
last administration of study drug.
Patients will be followed for the shortest of 1) three months after the last protocol based
treatment, or 2) the date other therapy is initiated.
;
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02194452 -
Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors
|
N/A | |
Completed |
NCT00053963 -
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
|
Phase 1 | |
Active, not recruiting |
NCT03233204 -
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
Completed |
NCT00091182 -
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
|
Phase 2 | |
Completed |
NCT00095940 -
Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00052780 -
Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors
|
Phase 1 | |
Completed |
NCT00004078 -
Irinotecan in Treating Children With Refractory Solid Tumors
|
Phase 2 | |
Completed |
NCT00100880 -
Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors
|
Phase 1 | |
Recruiting |
NCT02359565 -
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
|
Phase 1 | |
Terminated |
NCT01088763 -
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
|
Phase 1 | |
Completed |
NCT00326664 -
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
|
Phase 1 | |
Completed |
NCT00101270 -
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
|
Phase 1 | |
Active, not recruiting |
NCT03210714 -
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
Completed |
NCT00363272 -
Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma
|
Phase 1 | |
Completed |
NCT00946335 -
ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors
|
Phase 1 | |
Completed |
NCT01462695 -
Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma
|
Phase 2 | |
Completed |
NCT03387020 -
Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors
|
Phase 1 | |
Active, not recruiting |
NCT00638898 -
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
|
Phase 1 | |
Recruiting |
NCT05857969 -
Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
|
||
Completed |
NCT03860376 -
Ex Vivo Drug Sensitivity Testing and Mutation Profiling
|